Article | April 21, 2020

Direct-To-Patient Model Keeps Research Moving And Patients Safe

By Andrea Ochoa and Victoria Watts

Coronavirus Telemedicine Telehealth

In an effort to maintain the continuity of our clinical trials during the COVID-19 pandemic, Premier Research is helping customers take steps to safeguard the well-being of patients who were previously expected to go to a medical facility to receive treatment.

A Direct-to-Patient (DTP) model applies only to studies for which the sponsor has had site closures as a result of COVID-19 and has requested direct shipping from the site to a patient’s home. Various factors have to be taken into consideration in the risk assessments, such as the ability of the patients to receive and self-administer the drug, the shipping conditions required, or whether the presence of a home nurse is necessary to facilitate administration. By following this process, we have identified those clinical studies that can be done virtually and for which the study drug can be shipped directly to patients.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: